Pfizer mulls buying Strides Arcolab's Agila Specialties - report
Reuters | Updated On: January 15, 2013 10:24 (IST)
Pfizer is considering buying India's Agila Specialties, the injectable-medicines unit of Indian drug supplier Strides Arcolab, for a possible price of $2 billion (Rs 10,886.31 crore), Bloomberg reported on Monday.
Pfizer is doing due diligence and a deal could be reached this quarter, Bloomberg reported, citing unnamed sources.
A Pfizer spokeswoman said the company does not comment on market rumours or speculation.
Agila makes cancer treatments and antibiotics, Bloomberg said.
Copyright @ Thomson Reuters 2013
|For Profit Update,